Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Trial Details

NCT ID
NCT06976476
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • IgPro20
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Diagnosis of RRMM receiving a commercially available bispecific antibody
  • Received at least 1 but no more than 4 cycles of BsAb
  • Males or females greater than or equal to 18 years old at the time of consent
  • Life expectancy \> 12 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →